Please ensure Javascript is enabled for purposes of website accessibility

Why CytoSorbents Stock Got Clobbered Today

By Keith Speights – Jul 21, 2020 at 3:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A stock offering overshadowed the company's impressive preliminary second-quarter results.

What happened

Shares of CytoSorbents (CTSO -7.65%) were getting clobbered on Tuesday, with the stock sinking 15.9% as of 3:14 p.m. EDT. The big decline came after the maker of blood purification technologies announced a $40 million public offering late Monday afternoon.

So what

It shouldn't be surprising in the least that CytoSorbents decided to sell additional shares to raise cash. The healthcare stock is up more than 150% year to date even with today's drop. Companies often take advantage of higher share prices to build their cash positions.

Man looking at red line crashing through the floor

Image source: Getty Images.

CytoSorbents doesn't desperately need additional money, though. The company announced preliminary second-quarter results on Monday. Its cash balance at the end of June was around $35.1 million. With a cash burn of only around $2.3 million during the first half of 2020, CytoSorbents appears to be in a strong financial position. 

The COVID-19 pandemic has created robust demand for CytoSorbents' blood purification technology. Revenue in Q2 soared 58% to $9.8 million thanks largely to a surge in U.S. hospital sales of CytoSorb. The product, which adsorbs cytokines and reduces inflammation caused by "cytokine storms," received FDA emergency use authorization for use in treating COVID-19 patients in April.

Now what

Two key things to watch with CytoSorbents going forward are its Refresh 2-AKI clinical trial of CytoSorb and the launch of the product in nine Latin American countries. CytoSorbents hopes to provide top-line data from the Refresh 2-AKI study this quarter.  

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cytosorbents Stock Quote
$1.69 (-7.65%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.